AGP Picks
View all

Rekovelle market report flags IVF demand and regional growth shifts

Nov. 11, 2026
Rekovelle market report flags IVF demand and regional growth shifts
By AI, Created 17:00 UTC, Nov 11, 2026, AGP -

The Business Research Company says the global Rekovelle market will keep expanding through 2035, driven by rising infertility rates, more IVF procedures and broader use of personalized fertility treatment. Europe held the largest share in 2025, while Asia-Pacific is projected to grow fastest as access to reproductive care widens.

Why it matters: - Rekovelle is used in IVF and other assisted reproductive procedures, so demand for the drug tracks broader changes in fertility care. - Rising infertility rates and expanding access to reproductive health services are pushing more patients toward hormone-based fertility treatments. - The report points to a market shaped by clinical need, treatment innovation and regional differences in healthcare access.

What happened: - The Business Research Company published its Rekovelle Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Rekovelle market has grown on the back of higher infertility rates, more assisted reproductive technology clinics, later maternal age, better access to fertility drugs and support for recombinant hormone therapies. - The company says the market is expected to keep expanding through 2026 and beyond, with IVF procedure growth, personalized fertility treatment and fertility tourism as key drivers. - The report includes a free sample and full version available through the company's website: Download a free sample and View the full report.

The details: - Rekovelle contains follitropin delta, a recombinant hormone used to stimulate ovarian follicle growth in women undergoing IVF. - The drug is designed to promote the development of multiple eggs, which can improve the chances of fertilization and pregnancy. - The report identifies wider adoption of tailored fertility treatments, more frequent use of recombinant gonadotropins, individualized ovarian stimulation protocols, higher IVF volumes and more precise hormonal dosing as key trends. - The World Health Organization reported in April 2023 that about 17.5% of the global adult population, or roughly one in six people, experience infertility. - The report also cites genetic disorders as a growth driver, linking rising parental age to more DNA mutations and fertility challenges. - Gene People reported in March 2024 that genetic conditions affect around 1 in 25 children and more than 2.4 million people in the UK. - Europe held the largest share of the Rekovelle market in 2025 because of established healthcare infrastructure and broad use of advanced fertility treatments. - Asia-Pacific is expected to post the fastest growth during the forecast period, supported by rising infertility rates, greater awareness and expanding healthcare access. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The market opportunity is less about one drug alone and more about the growing scale of IVF and personalized fertility care. - The regional split suggests mature markets are leading in adoption, while faster-growing regions are still catching up on access and awareness. - The emphasis on more precise dosing and individualized protocols points to a broader shift toward treatment customization in reproductive medicine.

What's next: - The report expects continued demand growth as IVF volumes rise and fertility tourism expands. - Ongoing innovation in hormonal stimulation therapies is likely to shape both prescribing patterns and product demand. - Asia-Pacific's growth could narrow the gap with Europe if access to reproductive healthcare keeps improving.

The bottom line: - Rekovelle's market outlook is tied to a bigger fertility-care tailwind: more infertility, more IVF and more personalized treatment approaches.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

International Tech Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

International Tech Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.